促红细胞生成素——是时候重新评估了。 - Suppr

Suppr

超能文献

Erythropoiesis-stimulating agents--time for a reevaluation.

作者信息

Unger Ellis F, Thompson Aliza M, Blank Melanie J, Temple Robert

机构信息

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

出版信息

N Engl J Med. 2010 Jan 21;362(3):189-92. doi: 10.1056/NEJMp0912328. Epub 2010 Jan 6.

DOI:10.1056/NEJMp0912328

PMID:20054037

Abstract

摘要

相似文献

Erythropoiesis-stimulating agents--time for a reevaluation.

N Engl J Med. 2010 Jan 21;362(3):189-92. doi: 10.1056/NEJMp0912328. Epub 2010 Jan 6.

Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).

Nephrol Dial Transplant. 2010 Jun;25(6):1734-7. doi: 10.1093/ndt/gfq099. Epub 2010 Mar 2.

Treatment of anemia in chronic kidney disease--strategies based on evidence.

N Engl J Med. 2009 Nov 19;361(21):2089-90. doi: 10.1056/NEJMe0909664. Epub 2009 Oct 30.

Darbepoetin alfa and chronic kidney disease.

N Engl J Med. 2010 Feb 18;362(7):654; author reply 655.

An ongoing study of anemia correction in chronic kidney disease.

N Engl J Med. 2007 Mar 1;356(9):959-61. doi: 10.1056/NEJMc066568.

Darbepoetin alfa and chronic kidney disease.

N Engl J Med. 2010 Feb 18;362(7):654-5; author reply 655.

Emerging drugs for treatment of anemia of chronic kidney disease.

Expert Opin Emerg Drugs. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Epub 2013 Sep 16.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.

Chronic kidney disease anemia management: what should be done?

Blood Purif. 2011;31(1-3):186-8. doi: 10.1159/000321852. Epub 2011 Jan 10.

Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.

Expert Opin Drug Saf. 2009 Mar;8(2):145-53. doi: 10.1517/14740330902793031.

引用本文的文献

The Efficacy and Safety of a Personalized Protocol Designed to Balance Hemoglobin Levels in Hemodialysis Patients as Led by Nephrology Clinical Nurse Specialists: An Intervention Study.

Healthcare (Basel). 2025 Jun 2;13(11):1317. doi: 10.3390/healthcare13111317.

Comprehensive Strategies for Preoperative Pulmonary Risk Evaluation and Management.

Tuberc Respir Dis (Seoul). 2025 Jan;88(1):90-108. doi: 10.4046/trd.2024.0118. Epub 2024 Oct 30.

Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study.

Intern Med. 2025 May 1;64(9):1303-1314. doi: 10.2169/internalmedicine.3773-24. Epub 2024 Oct 17.

New horizons for reduction of blood use: Patient blood management.

Asian J Transfus Sci. 2023 Jan-Jun;17(1):108-116. doi: 10.4103/ajts.ajts_14_21. Epub 2022 Dec 12.

Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020.

Kidney Med. 2022 Dec 7;5(2):100578. doi: 10.1016/j.xkme.2022.100578. eCollection 2023 Feb.

Current Practices and Guidelines for Perioperative Blood Management in Post-Bariatric Body Contouring Surgery: A Comprehensive Review of Literature.

Aesthetic Plast Surg. 2023 Aug;47(4):1462-1471. doi: 10.1007/s00266-022-03192-z. Epub 2022 Nov 28.

Effect of vitamin and mineral supplementation on nutritional status in children with chronic kidney disease: Protocol for a systematic review and meta-analysis.

Medicine (Baltimore). 2022 Oct 28;101(43):e31518. doi: 10.1097/MD.0000000000031518.

Clinical Application Effects of Different Preoperative Blood Management Schemes in Older Patients with Delayed Intertrochanteric Fracture Surgery.

Clin Interv Aging. 2022 May 20;17:825-835. doi: 10.2147/CIA.S362020. eCollection 2022.

Dynamics of Erythroferrone Response to Erythropoietin in Rats.

Front Pharmacol. 2022 Apr 20;13:876573. doi: 10.3389/fphar.2022.876573. eCollection 2022.

Roxadustat for CKD-related Anemia in Non-dialysis Patients.

Kidney Int Rep. 2020 Dec 5;6(3):624-635. doi: 10.1016/j.ekir.2020.11.034. eCollection 2021 Mar.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Erythropoiesis-stimulating agents--time for a reevaluation.

N Engl J Med. 2010 Jan 21;362(3):189-92. doi: 10.1056/NEJMp0912328. Epub 2010 Jan 6.

Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA).

Nephrol Dial Transplant. 2010 Jun;25(6):1734-7. doi: 10.1093/ndt/gfq099. Epub 2010 Mar 2.

Treatment of anemia in chronic kidney disease--strategies based on evidence.

N Engl J Med. 2009 Nov 19;361(21):2089-90. doi: 10.1056/NEJMe0909664. Epub 2009 Oct 30.

Darbepoetin alfa and chronic kidney disease.

N Engl J Med. 2010 Feb 18;362(7):654; author reply 655.

An ongoing study of anemia correction in chronic kidney disease.

N Engl J Med. 2007 Mar 1;356(9):959-61. doi: 10.1056/NEJMc066568.

Darbepoetin alfa and chronic kidney disease.

N Engl J Med. 2010 Feb 18;362(7):654-5; author reply 655.

Emerging drugs for treatment of anemia of chronic kidney disease.

Expert Opin Emerg Drugs. 2013 Dec;18(4):421-9. doi: 10.1517/14728214.2013.836490. Epub 2013 Sep 16.

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.

Chronic kidney disease anemia management: what should be done?

Blood Purif. 2011;31(1-3):186-8. doi: 10.1159/000321852. Epub 2011 Jan 10.

Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.

Expert Opin Drug Saf. 2009 Mar;8(2):145-53. doi: 10.1517/14740330902793031.

引用本文的文献

The Efficacy and Safety of a Personalized Protocol Designed to Balance Hemoglobin Levels in Hemodialysis Patients as Led by Nephrology Clinical Nurse Specialists: An Intervention Study.

Healthcare (Basel). 2025 Jun 2;13(11):1317. doi: 10.3390/healthcare13111317.

Comprehensive Strategies for Preoperative Pulmonary Risk Evaluation and Management.

Tuberc Respir Dis (Seoul). 2025 Jan;88(1):90-108. doi: 10.4046/trd.2024.0118. Epub 2024 Oct 30.

Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study.

Intern Med. 2025 May 1;64(9):1303-1314. doi: 10.2169/internalmedicine.3773-24. Epub 2024 Oct 17.

New horizons for reduction of blood use: Patient blood management.

Asian J Transfus Sci. 2023 Jan-Jun;17(1):108-116. doi: 10.4103/ajts.ajts_14_21. Epub 2022 Dec 12.

Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020.

Kidney Med. 2022 Dec 7;5(2):100578. doi: 10.1016/j.xkme.2022.100578. eCollection 2023 Feb.

Current Practices and Guidelines for Perioperative Blood Management in Post-Bariatric Body Contouring Surgery: A Comprehensive Review of Literature.

Aesthetic Plast Surg. 2023 Aug;47(4):1462-1471. doi: 10.1007/s00266-022-03192-z. Epub 2022 Nov 28.

Effect of vitamin and mineral supplementation on nutritional status in children with chronic kidney disease: Protocol for a systematic review and meta-analysis.

Medicine (Baltimore). 2022 Oct 28;101(43):e31518. doi: 10.1097/MD.0000000000031518.

Clinical Application Effects of Different Preoperative Blood Management Schemes in Older Patients with Delayed Intertrochanteric Fracture Surgery.

Clin Interv Aging. 2022 May 20;17:825-835. doi: 10.2147/CIA.S362020. eCollection 2022.

Dynamics of Erythroferrone Response to Erythropoietin in Rats.

Front Pharmacol. 2022 Apr 20;13:876573. doi: 10.3389/fphar.2022.876573. eCollection 2022.

Roxadustat for CKD-related Anemia in Non-dialysis Patients.

Kidney Int Rep. 2020 Dec 5;6(3):624-635. doi: 10.1016/j.ekir.2020.11.034. eCollection 2021 Mar.